VIENNA, Va., Oct. 29 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(Amex: CVM) announced today that it has published a very comprehensive
review of cancer immunotherapies on its new website. The link is located in
the top right hand corner of its home page at http://www.cel-sci.com .
Geert Kersten, Chief Executive Officer of CEL-SCI said, "Immunotherapy
in the minds of many represents the future of cancer therapy. We have
created an easy to navigate, interactive web based review that is designed
to be helpful to doctors, patients as well as investors."
CEL-SCI Corporation is developing products that empower immune
defenses. Its lead product is Multikine(R). In Phase II clinical trials
Multikine was shown to be safe and well-tolerated, and to improve the
patients' overall survival by 33% at a median of three and a half years
following surgery. The U.S. Food and Drug Administration (FDA) gave the
go-ahead for a Phase III clinical trial with Multikine in January 2007 and
granted orphan drug status to Multikine as a neoadjuvant therapy of
squamous cell carcinoma (cancer) of the head and neck in May 2007.
The Company has operations in Vienna, Virginia and Baltimore, Maryland.
CEL-SCI's other products, which are currently in pre-clinical stage, have
shown protection against a number of diseases in animal tests and are being
tested against diseases associated with bio-defense.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460, Fax, +1-703-506-9471
|
